MALIGNANT FIBROUS HISTIOCYTOMA. THE RESULTS OF COMBINED TREATMENT OF RESECTABLE FORMS

Сехина О. В.; Федянин М. Ю.; Яковлева Е. С.; Буланов А. А.; Бохян Б. Ю.; O. V. Sekhina; M. U. Fedyanin; E. S. Yakovleva; A. A. Bulanov; B. Y. Bokhyan

MALIGNANT FIBROUS HISTIOCYTOMA. THE RESULTS OF COMBINED TREATMENT OF RESECTABLE FORMS

Authors: ¹, ¹, ¹, ¹, ¹, Sekhina O.V.², Fedyanin M.U.², Yakovleva E.S.², Bulanov A.A.², Bokhyan B.Y.²
Affiliations:
1. Российский онкологический научный центр им. Н.Н. Блохина РАМН
2. N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Issue: Vol 3, No 4 (2011)
Pages: 37-40
Section: Articles
Published: 11.11.2011
URL: https://sarbon.abvpress.ru/jour/article/view/253
ID: 253

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Background. We studied the patients' outcome with respectable forms of malignant fibrous histiocytoma according to the
type of chemotherapy. Methods. We performed a retrospective analysis of 53 patients with malignant fibrous histiocytoma treated in the N.N. Blokhins
Russian Cancer Research Center from 2000 to 2010. All patients underwent radical surgery. Neoadjuvant chemotherapy
was administered in 7 (13%) patients, adjuvant chemotherapy - in 5 (9%), neo and adjuvant chemotherapy - in 13 (24%)
patients, chemotherapy was not done in 28 (54%) patients. Result. Progression of the disease was revealed in 6/7 (86%), 7/18 (39%), 17/28 (60%) respectively. Conclusion. Patients with MFH should be prescribed adjuvant chemotherapy for reducing the risk of relapse.